Global BCG Vaccine for Tuberculosis (TB) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global BCG Vaccine for Tuberculosis (TB) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
BCG Vaccine for Tuberculosis (TB) provides immunity or protection against tuberculosis (TB). The vaccine may be given to persons at high risk of developing TB.
BCG Vaccine for Tuberculosis (TB) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global BCG Vaccine for Tuberculosis (TB) market is projected to reach US$ 549.6 million in 2029, increasing from US$ 373.9 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2029. Demand from Hospitals and Clinics are the major drivers for the industry.
The BCG (Bacillus Calmette-Guérin) vaccine for tuberculosis (TB) is driven by several key factors that influence the demand for this vaccine and its role in addressing the global TB burden
Tuberculosis PrevalenceTB remains a significant global health issue, especially in regions with high prevalence rates. The BCG vaccine is used as a preventive measure in areas with a high burden of TB cases.
TB Control and Eradication EffortsThe BCG vaccine is a critical tool in the fight against TB, supporting efforts to control the spread of the disease and eventually work towards its eradication.
Childhood Immunization ProgramsMany countries include the BCG vaccine as a part of their childhood immunization schedules to protect infants and children against TB.
Protection Against Severe FormsThe BCG vaccine is particularly effective in protecting children against severe forms of TB, such as TB meningitis and disseminated TB.
Healthcare Worker ProtectionHealthcare workers, especially those in regions with a high TB burden, may receive the BCG vaccine to reduce their risk of TB infection.
Reducing TB-Related MortalityThe BCG vaccine contributes to reducing TB-related mortality, especially in high-risk populations such as infants and individuals with compromised immune systems.
Drug-Resistant TB PreventionIn regions with drug-resistant TB strains, the BCG vaccine can help prevent the development of severe forms of TB and reduce the risk of transmission.
Global Health InitiativesOrganizations such as the World Health Organization (WHO) promote the use of the BCG vaccine as part of global TB control strategies.
High-Risk PopulationsThe BCG vaccine is often recommended for individuals at higher risk of TB exposure, such as those living in crowded or high-risk areas.
Public Health AwarenessPublic health campaigns and awareness efforts promote the importance of TB prevention through vaccination, driving demand for the BCG vaccine.
TB Elimination GoalsMany countries have set goals to eliminate TB as a public health threat. The BCG vaccine plays a role in achieving these goals.
Immunity BuildingThe BCG vaccine is known to enhance the immune response, potentially offering some level of protection against other respiratory infections.
Global Travel and MigrationTB transmission can occur through global travel and migration. The BCG vaccine may be recommended for individuals traveling to or from regions with high TB prevalence.
Research and DevelopmentOngoing research aims to improve the effectiveness and administration of the BCG vaccine, which could increase its adoption and impact.
Integration into Routine Immunization ProgramsThe integration of the BCG vaccine into routine immunization programs helps ensure that a larger portion of the population receives the vaccine.
Collaboration and FundingPartnerships between governments, international organizations, and healthcare institutions drive the availability and accessibility of the BCG vaccine.
Pandemic PreparednessThe ongoing COVID-19 pandemic has highlighted the importance of vaccine-preventable diseases, potentially increasing interest in vaccine research and development, including the BCG vaccine.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global BCG Vaccine for Tuberculosis (TB) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
AJ Vaccines
Serum Institute of India
Intervax
GSBPL
Statens Serum Institute
Biomed Lublin
ANLIS Malbran
Fundação Ataulpho de Paiva
BB-NCIPD
Taj Pharmaceuticals
Bio Farma
Microgen
Torlakinstitut
Institut Pasteur de Tunis
IVAC
Segment by Type
Immune Type
Therapy Type
Hospitals
Clinics
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the BCG Vaccine for Tuberculosis (TB) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of BCG Vaccine for Tuberculosis (TB), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the BCG Vaccine for Tuberculosis (TB) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of BCG Vaccine for Tuberculosis (TB) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, BCG Vaccine for Tuberculosis (TB) introduction, etc. BCG Vaccine for Tuberculosis (TB) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of BCG Vaccine for Tuberculosis (TB) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
BCG Vaccine for Tuberculosis (TB) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global BCG Vaccine for Tuberculosis (TB) market is projected to reach US$ 549.6 million in 2029, increasing from US$ 373.9 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2029. Demand from Hospitals and Clinics are the major drivers for the industry.
The BCG (Bacillus Calmette-Guérin) vaccine for tuberculosis (TB) is driven by several key factors that influence the demand for this vaccine and its role in addressing the global TB burden
Tuberculosis PrevalenceTB remains a significant global health issue, especially in regions with high prevalence rates. The BCG vaccine is used as a preventive measure in areas with a high burden of TB cases.
TB Control and Eradication EffortsThe BCG vaccine is a critical tool in the fight against TB, supporting efforts to control the spread of the disease and eventually work towards its eradication.
Childhood Immunization ProgramsMany countries include the BCG vaccine as a part of their childhood immunization schedules to protect infants and children against TB.
Protection Against Severe FormsThe BCG vaccine is particularly effective in protecting children against severe forms of TB, such as TB meningitis and disseminated TB.
Healthcare Worker ProtectionHealthcare workers, especially those in regions with a high TB burden, may receive the BCG vaccine to reduce their risk of TB infection.
Reducing TB-Related MortalityThe BCG vaccine contributes to reducing TB-related mortality, especially in high-risk populations such as infants and individuals with compromised immune systems.
Drug-Resistant TB PreventionIn regions with drug-resistant TB strains, the BCG vaccine can help prevent the development of severe forms of TB and reduce the risk of transmission.
Global Health InitiativesOrganizations such as the World Health Organization (WHO) promote the use of the BCG vaccine as part of global TB control strategies.
High-Risk PopulationsThe BCG vaccine is often recommended for individuals at higher risk of TB exposure, such as those living in crowded or high-risk areas.
Public Health AwarenessPublic health campaigns and awareness efforts promote the importance of TB prevention through vaccination, driving demand for the BCG vaccine.
TB Elimination GoalsMany countries have set goals to eliminate TB as a public health threat. The BCG vaccine plays a role in achieving these goals.
Immunity BuildingThe BCG vaccine is known to enhance the immune response, potentially offering some level of protection against other respiratory infections.
Global Travel and MigrationTB transmission can occur through global travel and migration. The BCG vaccine may be recommended for individuals traveling to or from regions with high TB prevalence.
Research and DevelopmentOngoing research aims to improve the effectiveness and administration of the BCG vaccine, which could increase its adoption and impact.
Integration into Routine Immunization ProgramsThe integration of the BCG vaccine into routine immunization programs helps ensure that a larger portion of the population receives the vaccine.
Collaboration and FundingPartnerships between governments, international organizations, and healthcare institutions drive the availability and accessibility of the BCG vaccine.
Pandemic PreparednessThe ongoing COVID-19 pandemic has highlighted the importance of vaccine-preventable diseases, potentially increasing interest in vaccine research and development, including the BCG vaccine.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global BCG Vaccine for Tuberculosis (TB) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
AJ Vaccines
Serum Institute of India
Intervax
GSBPL
Statens Serum Institute
Biomed Lublin
ANLIS Malbran
Fundação Ataulpho de Paiva
BB-NCIPD
Taj Pharmaceuticals
Bio Farma
Microgen
Torlakinstitut
Institut Pasteur de Tunis
IVAC
Segment by Type
Immune Type
Therapy Type
Segment by Application
Hospitals
Clinics
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the BCG Vaccine for Tuberculosis (TB) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of BCG Vaccine for Tuberculosis (TB), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the BCG Vaccine for Tuberculosis (TB) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of BCG Vaccine for Tuberculosis (TB) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, BCG Vaccine for Tuberculosis (TB) introduction, etc. BCG Vaccine for Tuberculosis (TB) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of BCG Vaccine for Tuberculosis (TB) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices